Snape S, Moyle G, Goll A, Warburg M, Little F; International Conference on AIDS.
Int Conf AIDS. 1993 Jun 6-11; 9: 467 (abstract no. PO-B26-1989).
European ddC Coordinating Centre, Berlin, Germany.
OBJECTIVE: To assess the incidence of adverse events (AE), in HIV positive individuals receiving ddC therapy. METHODS: Patients enrolling in a European expanded access programme providing ddC to patients intolerant to ZDV were followed at 4 week intervals by clinic attendance to assess presence of AE and specifically peripheral neuropathy (PN). RESULTS: 285 patients have been enrolled thus far in this ongoing study. Data on at least one attendance was available for 176 patients. Table 1 shows the incidence of the most common AE thought possibly or probably related to ddC. Table 2 shows a subgroup analysis of patients who developed PN (data not available in some patients). TABULAR DATA, SEE ABSTRACT VOLUME. CONCLUSIONS: This is the first study of ddC in European patients. No unexpected AE have reported. No pancreatitis has been reported. The incidence of the most frequent AE are similar to those reported in US studies. Peripheral neuropathy is most likely to develop in patients who commence ddC with a diagnosis of AIDS and a CD4 count < 50 cell/mm3.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- CD4 Lymphocyte Count
- CD4-Positive T-Lymphocytes
- Disease Progression
- Ethnic Groups
- HIV Seropositivity
- Humans
- Incidence
- Peripheral Nervous System Diseases
- Zalcitabine
- Zidovudine
Other ID:
UI: 102204972
From Meeting Abstracts